Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
930.20
1.35 (0.15%) Zydus Lifesciences informs about press release
Date: 02-06-2025Zydus Lifesciences has informed that it enclosed a copy of press release dated June 2, 2025, titled ‘Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg.’
The above information is a part of company’s filings submitted to BSE.